In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drugs And Rare Diseases Top EU Approvals In 2015

This article was originally published in SRA

Executive Summary

  • 46 new active substances approved
  • First stem cell therapy
  • First drug for mitochondrial dysfunction
  • 12 new anticancers
  • 16 drugs for rare diseases
  • Five accelerated approvals
  • Four conditional approvals
  • Three exceptional circumstances approvals
  • Second-highest number of CHMP recommendations
  • You may also be interested in...

    

    Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesevir Filing

    Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic. 

    Subgroups & Missing Data: The Problems Facing HTAs In Europe

    The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.

    Fair Prices Call Prompts EU Industry To Insist On Innovation Incentives

    Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.

    UsernamePublicRestriction

    Register

    WI965023

    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel